COMPANY PROFILE

Ategrity

Explore full profile

Excess and surplus insurance for small and medium-sized businesses

Scottsdale, United StatesFounded 2018Energy

Valuation $1–2.5B Last recorded · 2026

Revenue $500M–1B Latest reported FY

Headcount 100–500 Current team size

Total funding $100–500M Disclosed equity funding

Unlock exact values

About Ategrity

Ategrity Specialty Insurance Company (Ategrity) is an excess and surplus (E&S) lines insurance company headquartered in Scottsdale, Arizona, with executive offices in New York. Founded in 2018, it underwrites property and casualty risks for small and medium-sized businesses through a network of wholesale brokers and agents across the United States, using data-driven, technology-enabled underwriting to price complex and hard-to-place risks. Its product lines include professional liability, healthcare liability and other commercial casualty coverages. Ategrity is backed by Sequentis, the investment vehicle of the Zimmer family, and listed on the New York Stock Exchange under the ticker ASIC in June 2025.

MoreLess Source: Dealroom company data

At a glance

Status: Operational
Founded: 2018
Headquarters: Scottsdale, United States
Employees: 180
Open positions: 32
Dealroom signal: 86.0/100
Industry: Energy, Marketing
Sub-industry: CRM & Sales
Sector: Energy, Hard Tech, horizontal marketplaces
Business model: Marketplace & ecommerce
Client focus: b2b
Links: Website X

Knowledge graph

Founder mafia, market maps, research and news connected to this company by Dealroom

Funding history

3 recorded events

Company financing events and reported valuations.

Deal type	Date	Amount	Valuation	Investors	Source
IPOOther financing	Jun 2025	—	$706M	Undisclosed	↗
GROWTH EQUITY VCOther financing	Sep 2022	$75M	—	Zimmer Financial Services	↗

Showing the latest 2 of 3 recorded eventsBook a demo for the full funding history →

Financials

Revenue over time

Revenue, earnings and other financial measures where available. Years marked “E” are estimates.

Year	Revenue	Growth
2026
2025
2024
2023		—

Company filings, research estimates and Dealroom dataBook a demo for the full financial model →

Growth signals

Ategrity website traffic

Latest recorded traffic for Ategrity is 4.4K monthly website visits, up 51.7% over the last three months. Ategrity's team grew 3.4% over the past year.

Latest monthly visits4.4K 3-month web change+51.7% 1-year team growth+3.4%

Monthly website visitsDec 2018–Jul 2026

Explore monthly traffic historyTrack growth over time and compare with peersBook a demo

Summary metrics are public; monthly history is available with a demoCompare with peers →

Open positions

Openings linked to this company in Dealroom

Partner Success Manager14000 N Pima Rd, Scottsdale, Arizona 85260, US · Marketing & Communication · Sep 5, 2026 Underwriter, Middle Market Casualty - Construction14000 N Pima Rd, Scottsdale, Arizona 85260, US · Other · Sep 3, 2026 Strategic Partnership Manager14000 N Pima Rd, Scottsdale, Arizona 85260, US · Business Development · Aug 28, 2026 Management & Professional Liability Claims AdjusterAtlanta Metropolitan Area · Accounting · Aug 26, 2026 AVP, Underwriting - Life SciencesRichmond, VA · Other · Aug 26, 2026 Finance Project ManagerManhattan, NY · Finance · Aug 25, 2026 AVP, Underwriting - Environmental LiabilityScottsdale, AZ · Legal · Aug 25, 2026 Premium AuditorScottsdale, AZ · Accounting · Aug 23, 2026

8 distinct openings shownExplore hiring signals →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Company	Headquarters	Status	Employees	Total funding	Valuation
EVEversensNon-invasive diagnostic solutions for breath analysis	Pamplona, Spain	Operational	13	$781K	$1.6M
SSSecondWave SystemsDeveloping a novel, ultrasound-based wearable neuromodulation platform	Minneapolis, United States	Operational
FUFunPepFunPep is an Industry-university collaboration bioventure company	Ibaraki, Japan	Operational
AIArterial Health InternationalProvides clinical diagnostic tests for a comprehensive evaluation of cardiovascular disease risk factors	Atlanta, United States	Operational
TBTAGCyx BiotechnologiesCreating candidate compounds for high-performance nucleic acid drugs with high affinity and specificity for target molecules using our proprietary nucleic acid basic technology	Tokyo, Japan	Acquired
ANAmygdala NeuroscienceAmygdala's mission is to address the growing unmet need associated with substance use disorder by discovering, developing and commercializing safe and effective pharmacotherapies to treat and prevent addiction	Palo Alto, United States	Operational
ATAnHeart TherapeuticsPrecision medicine biopharmaceutical company leveraging expertise in clinical research and development and product registration focusing initially on oncology products	Huangpu, China	Acquired
CBContraria BiotechDevelops innovative, cost-effective therapeutic and prophylactic drugs to combat global health challenges like antibiotic resistance, emerging diseases, and pandemics	Siena, Italy	Operational